Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Digestive SystemDRG 379-gastrointestinal-hemorrhage-without-cc-mcc
    Ask Trek AI about this page

    Gastrointestinal Hemorrhage without CC/MCC: Inpatient Reimbursement Overview

    DRG 379 addresses inpatient stays for gastrointestinal hemorrhage without a Major Complication or Comorbidity or Complication or Comorbidity, covering cases that require hospital management but lack higher-severity comorbid conditions. This classification matters for inpatient reimbursement because Medicare Diagnosis-Related Group payment is assigned by DRG and severity level, which determines the standardized prospective payment for these admissions.

    Customize your policy alerts

    Sign up for drg 379 policy alerts

    Get alerted when payer policies referencing 379 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 379 Overview

    DRG 379 covers inpatient admissions for patients with gastrointestinal bleeding that do not have a Major Complication or Comorbidity or a Complication or Comorbidity. This category captures cases where bleeding requires hospital evaluation and management but without higher-severity comorbid conditions that increase resource use. It matters for Medicare payment because lump-sum Diagnosis-Related Group reimbursement is based on assigned DRG severity and influences hospital reimbursement for these common acute admissions. Understanding this DRG helps clarify expected payment classification and resource implications for uncomplicated gastrointestinal hemorrhage cases.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute hemostatic intervention trials: randomized or pragmatic studies testing different endoscopic, interventional radiology, or pharmacologic strategies to achieve and sustain hemostasis in patients admitted with active upper or lower gastrointestinal bleeding without major comorbid complications. These trials typically enroll adults presenting to the emergency department or hospital with confirmed GI hemorrhage (e.g., peptic ulcer bleeding, diverticular bleed, angiodysplasia) and compare immediate procedural approaches, timing of endoscopy, or short-term adjunctive medications to reduce transfusion needs and rebleeding. Results are directly relevant to hospital clinicians and payers because they inform resource use during the index admission (length of stay, procedural utilization, transfusion frequency) and help define protocols that can reduce costly readmissions and complications.
    • Comparative effectiveness studies of risk stratification and care pathways: observational cohort studies or cluster-randomized evaluations that compare risk-scoring systems (such as adaptations of clinical severity scores), early discharge criteria, or standardized admission pathways (observation unit versus inpatient ward) for patients with non-severe GI hemorrhage without CC/MCC. These studies focus on patients who are hemodynamically stable or have limited transfusion requirements to determine which pathways safely minimize unnecessary inpatient days, diagnostic testing, and endoscopic timing. Findings are important for payers and hospitals aiming to allocate inpatient beds appropriately, lower avoidable costs, and maintain quality metrics by identifying which patients can be managed safely with less intensive inpatient resources.
    • Post-discharge outcomes and secondary prevention research: prospective cohort studies and pragmatic trials evaluating outpatient follow-up strategies, medication adherence programs, or secondary prevention interventions (for example, H. pylori eradication verification programs, anticoagulation management protocols, or surveillance planning) among survivors of GI hemorrhage without major complications. These investigations enroll discharged patients to measure rates of rebleeding, readmission, medication complications, and long-term functional outcomes, and to test interventions that reduce recurrence risk. This area matters to providers and payers because preventing recurrent bleeding and readmissions improves patient safety and lowers downstream costs associated with repeat hospitalizations and procedures.

    Related Codes

    326-STOMACH-ESOPHAGEAL-AND-DUODENAL-PROCEDURES-WITH-MCC

    Stomach, Esophageal and Duodenal Procedures with MCC: Inpatient Reimbursement Overview

    327-STOMACH-ESOPHAGEAL-AND-DUODENAL-PROCEDURES-WITH-CC

    Stomach, Esophageal and Duodenal Procedures with CC: Inpatient Reimbursement Overview

    328-STOMACH-ESOPHAGEAL-AND-DUODENAL-PROCEDURES-WITHOUT-CC-MCC

    Stomach, Esophageal and Duodenal Procedures without CC/MCC: Inpatient Reimbursement Overview

    329-MAJOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITH-MCC

    Major Small and Large Bowel Procedures with MCC: Inpatient Reimbursement Overview

    330-MAJOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITH-CC

    Major Small and Large Bowel Procedures with CC: Inpatient Reimbursement Overview

    331-MAJOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITHOUT-CC-MCC

    Major Small and Large Bowel Procedures without CC/MCC: Inpatient Reimbursement Overview

    332-RECTAL-RESECTION-WITH-MCC

    Rectal Resection with MCC: Inpatient Reimbursement Overview

    333-RECTAL-RESECTION-WITH-CC

    Rectal Resection with CC: Inpatient Reimbursement Overview

    334-RECTAL-RESECTION-WITHOUT-CC-MCC

    Rectal Resection without CC/MCC: Inpatient Reimbursement Overview

    335-PERITONEAL-ADHESIOLYSIS-WITH-MCC

    Peritoneal Adhesiolysis with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 57

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.